{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:58:54Z","timestamp":1790621934662,"version":"4.1.0"},"reference-count":136,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00639","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T07:12:51Z","timestamp":1523862771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":115,"title":["Complement Activation in Inflammatory Skin Diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Jenny","family":"Giang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A. J.","family":"Seelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn B. A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Errol P.","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15061","DOI":"10.1073\/pnas.1307855110","article-title":"Complement modulates the cutaneous microbiome and inflammatory milieu","volume":"110","author":"Chehoud","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement. Second of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1423-0410.1998.tb05434.x","article-title":"Complement regulation","volume":"74","author":"Meri","year":"1998","journal-title":"Vox Sang"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.molimm.2011.02.003","article-title":"Expression of complement components, receptors and regulators by human dendritic cells","volume":"48","author":"Li","year":"2011","journal-title":"Mol Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1016\/j.molimm.2007.01.007","article-title":"Human keratinocytes produce the complement inhibitor factor I: synthesis is regulated by interferon-gamma","volume":"44","author":"Timar","year":"2007","journal-title":"Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molimm.2005.02.009","article-title":"Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma","volume":"43","author":"Timar","year":"2006","journal-title":"Mol Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1046\/j.1365-2133.2002.04604.x","article-title":"Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo","volume":"146","author":"van den Wijngaard","year":"2002","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.it.2010.01.002","article-title":"Crosstalk pathways between toll-like receptors and the complement system","volume":"31","author":"Hajishengallis","year":"2010","journal-title":"Trends Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/BF00560390","article-title":"Structural aspects of initial psoriatic lesions","volume":"251","author":"Braun-Falco","year":"1974","journal-title":"Arch Dermatol Forsch"},{"key":"B11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/1523-1747.ep12558281","article-title":"Chemokinetic and chemotactic factors in psoriasis scale extracts","volume":"71","author":"Dahl","year":"1978","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.1976.tb15529.x","article-title":"Leukotactic properties of soluble substances in psoriasis scale","volume":"95","author":"Tagami","year":"1976","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2133.1977.tb05194.x","article-title":"Demonstration of C3 cleavage product in leukotactic substances of scale extract from pustular psoriasis","volume":"96","author":"Tagami","year":"1977","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/1523-1747.ep12506623","article-title":"Immunopathology of psoriasis: a comparison with other parakeratotic lesions","volume":"78","author":"Weiss","year":"1982","journal-title":"J Invest Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1034\/j.1600-0625.2001.100403.x","article-title":"Psoriasis scales contain C5a as the predominant chemotaxin for monocyte-derived dendritic cells","volume":"10","author":"Mrowietz","year":"2001","journal-title":"Exp Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/1523-1747.ep12523572","article-title":"Determination of anaphylatoxin concentrations in suction blisters in patients with psoriasis","volume":"87","author":"Ohkohchi","year":"1986","journal-title":"J Invest Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/1523-1747.ep12276664","article-title":"Transient absence of C5a-specific neutrophil function in inflammatory disorders of the skin","volume":"85","author":"Schr\u00f6der","year":"1985","journal-title":"J Invest Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2133.1986.tb02773.x","article-title":"Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses","volume":"114","author":"Takematsu","year":"1986","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2230.1996.tb00144.x","article-title":"Systemic complement activation in psoriasis vulgaris","volume":"21","author":"Fleming","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF00509233","article-title":"Involvement of complement in psoriasis and atopic dermatitis \u2013 measurement of C3a and C5a, C3, C4 and C1 inactivator","volume":"277","author":"Kapp","year":"1985","journal-title":"Arch Dermatol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2133.1985.tb02064.x","article-title":"Increased anaphylatoxins (C3a and C4a) in psoriatic sera","volume":"113","author":"Ohkohchi","year":"1985","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1620\/tjem.154.315","article-title":"Increased plasma concentrations of complement modulating proteins (C1 inhibitor, C4-binding protein, factor H and factor I) in psoriasis","volume":"154","author":"Ohkohchi","year":"1988","journal-title":"Tohoku J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2230.1990.tb02011.x","article-title":"Complement activation in psoriasis","volume":"15","author":"Rosenberg","year":"1990","journal-title":"Clin Exp Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2230.1982.tb02446.x","article-title":"Abnormalities in the alternative pathway of complement in psoriasis","volume":"7","author":"Marley","year":"1982","journal-title":"Clin Exp Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1046\/j.1365-2230.1998.00360.x","article-title":"Activation of complement in psoriasis","volume":"23","author":"Pasch","year":"1998","journal-title":"Clin Exp Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.clindermatol.2012.03.001","article-title":"Comparisons of pathologic and normal skin reactive autoantibodies and the interference phenomenon","volume":"30","author":"Beutner","year":"2012","journal-title":"Clin Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00447158","article-title":"Autoimmunity in psoriasis. Relation of disease activity and forms of psoriasis to immunofluorescence findings","volume":"261","author":"Jablonska","year":"1978","journal-title":"Arch Dermatol Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1126\/science.929193","article-title":"Polymorphonuclear leukocytes: possible mechanism of accumulation in psoriasis","volume":"198","author":"Lazarus","year":"1977","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/1523-1747.ep12709634","article-title":"Stratum corneum activation of complement through the antibody-independent alternative pathway","volume":"92","author":"Terui","year":"1989","journal-title":"J Invest Dermatol"},{"key":"B31","first-page":"21","article-title":"Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin?","volume":"107","author":"Valdimarsson","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF00509048","article-title":"Psoriatic leukotactic factor. Further physicochemical characterization and effect on the epidermal cells","volume":"272","author":"Tagami","year":"1982","journal-title":"Arch Dermatol Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.molimm.2006.12.014","article-title":"Expression of terminal complement components by human keratinocytes","volume":"44","author":"Timar","year":"2007","journal-title":"Mol Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/1523-1747.ep12285633","article-title":"C3 production of cultured human epidermal keratinocytes in enhanced by IFN\u03b3 and TNF\u03b1 through different pathways","volume":"108","author":"Terui","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00000372-197900130-00002","article-title":"Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation of clinical and histologic findings","volume":"1","author":"Ragaz","year":"1979","journal-title":"Am J Dermatopathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/jid.1961.36","article-title":"The capillary responses in psoriatic skin*","volume":"36","author":"Telner","year":"1961","journal-title":"J Invest Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/bjd.12631","article-title":"Bimodal immune activation in psoriasis","volume":"170","author":"Christophers","year":"2014","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1172\/JCI111724","article-title":"Studies of human C5a as a mediator of inflammation in normal human skin","volume":"75","author":"Yancey","year":"1985","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.immuni.2013.11.011","article-title":"S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3","volume":"39","author":"Schonthaler","year":"2013","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jid.2016.11.011","article-title":"Complement C3 exacerbates imiquimod-induced skin inflammation and psoriasiform dermatitis","volume":"137","author":"Giacomassi","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/pgmj.75.884.328","article-title":"Acne: a review of immunologic and microbiologic factors","volume":"75","author":"Burkhart","year":"1999","journal-title":"Postgrad Med J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0190-9622(95)90243-0","article-title":"Inflammation in acne vulgaris","volume":"33","author":"Webster","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/archderm.1966.01600210100020","article-title":"Corynebacterium acnes. Presence of complement fixing antibodies to Corynebacterium acnes in the sera of patients with acne vulgaris","volume":"93","author":"Puhvel","year":"1966","journal-title":"Arch Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2133.1979.tb05625.x","article-title":"Activation of complement-a mechanism for the inflammation in acne","volume":"101","author":"Scott","year":"1979","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/1523-1747.ep12676801","article-title":"An overview of acne","volume":"62","author":"Kligman","year":"1974","journal-title":"J Invest Dermatol"},{"key":"B46","first-page":"468","article-title":"The microbial content and complement C3 cleaving capacity of comedones in acne vulgaris","volume":"68","author":"Leeming","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2133.1978.tb01947.x","article-title":"Complement activation by Corynebacterium acnes","volume":"98","author":"Massey","year":"1978","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/IAI.26.1.183-186.1979","article-title":"Complement activation in acne vulgaris: consumption of complement by comedones","volume":"26","author":"Webster","year":"1979","journal-title":"Infect Immun"},{"key":"B49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/IAI.22.2.523-529.1978","article-title":"Complement activation in acne vulgaris: in vitro studies with Propionibacterium acnes and Propionibacterium granulosum","volume":"22","author":"Webster","year":"1978","journal-title":"Infect Immun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CCID.S111019","article-title":"Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment","volume":"10","author":"Napolitano","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2011.08.047","article-title":"Pathogenesis and pharmacotherapy of hidradenitis suppurativa","volume":"672","author":"Nazary","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","article-title":"Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments","volume":"21","author":"van der Zee","year":"2012","journal-title":"Exp Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/bjd.14371","article-title":"Gene expression profiling of skin and blood in hidradenitis suppurativa","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16428","article-title":"Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?","author":"Kanni","year":"2018","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"B58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2014.01.004","article-title":"Diagnostic criteria for systemic lupus erythematosus: a critical review","volume":"4","author":"Yu","year":"2014","journal-title":"J Autoimmun"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/j.1365-2133.2011.10272.x","article-title":"Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden","volume":"164","author":"Gronhagen","year":"2011","journal-title":"Br J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.autrev.2017.05.009","article-title":"Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema","volume":"16","author":"Zhang","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40257-016-0173-9","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment","volume":"17","author":"Hejazi","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-015-0706-2","article-title":"Pathophysiology of cutaneous lupus erythematosus","volume":"17","author":"Achtman","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/ijms140612222","article-title":"UV radiation and the skin","volume":"14","author":"D\u2019Orazio","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1191\/0961203303lu329oa","article-title":"Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus","volume":"12","author":"Racila","year":"2003","journal-title":"Lupus"},{"key":"B65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2133.2004.06308.x","article-title":"The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2\/C4 deficiency","volume":"152","author":"Boeckler","year":"2005","journal-title":"Br J Dermatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/art.39589","article-title":"Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in East Asian populations","volume":"68","author":"Chen","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1074-7613(00)80669-X","article-title":"A critical role for complement in maintenance of self-tolerance","volume":"9","author":"Prodeus","year":"1998","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","article-title":"Systemic lupus erythematosus, complement deficiency, and apoptosis","volume":"76","author":"Pickering","year":"2000","journal-title":"Adv Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/art.1780310401","article-title":"Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus","volume":"31","author":"Antes","year":"1988","journal-title":"Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/ard.49.9.698","article-title":"Significance of low molecular weight C1q in systemic lupus erythematosus","volume":"49","author":"Hoekzema","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.158.10.4525","article-title":"C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited","volume":"158","author":"Korb","year":"1997","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/imr.12462","article-title":"Complement in removal of the dead \u2013 balancing inflammation","volume":"274","author":"Martin","year":"2016","journal-title":"Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.179.4.1317","article-title":"Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes","volume":"179","author":"Casciola-Rosen","year":"1994","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1078\/0171-2985-00141","article-title":"C1q, autoimmunity and apoptosis","volume":"205","author":"Botto","year":"2002","journal-title":"Immunobiology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.4049\/jimmunol.0902642","article-title":"Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven","volume":"183","author":"Schaller","year":"2009","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.4049\/jimmunol.0803573","article-title":"Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells","volume":"183","author":"Bigler","year":"2009","journal-title":"J Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.4049\/jimmunol.1501659","article-title":"Anti-C1q autoantibodies from systemic lupus erythematosus patients induce a proinflammatory phenotype in macrophages","volume":"196","author":"Thanei","year":"2016","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/TCRM.S10145","article-title":"The lupus band test in systemic lupus erythematosus patients","volume":"7","author":"Reich","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"B79","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.humimm.2014.04.015","article-title":"Mannose binding lectin deposition in skin of lupus erythematosus patients: a case series","volume":"75","author":"Wallim","year":"2014","journal-title":"Hum Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B81","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/01.dad.0000181109.54532.c5","article-title":"Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis","volume":"27","author":"Carlson","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0190-9622(98)70039-8","article-title":"Cutaneous small-vessel vasculitis","volume":"39","author":"Lotti","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archderm.134.3.309","article-title":"Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients","volume":"134","author":"Sais","year":"1998","journal-title":"Arch Dermatol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-4362.1997.tb03094.x","article-title":"Leukocytoclastic vasculitis \u2013 correlation between different histologic stages and direct immunofluorescence results","volume":"36","author":"Grunwald","year":"1997","journal-title":"Int J Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-4632.2005.02898.x","article-title":"Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment","volume":"45","author":"Russell","year":"2006","journal-title":"Int J Dermatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2249.1993.tb03392.x","article-title":"Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers","volume":"92","author":"Dauchel","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0002-9440(10)63173-2","article-title":"C5a-induced gene expression in human umbilical vein endothelial cells","volume":"164","author":"Albrecht","year":"2004","journal-title":"Am J Pathol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1083\/jcb.131.3.775","article-title":"Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases","volume":"131","author":"Owen","year":"1995","journal-title":"J Cell Biol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0002-9343(87)90436-0","article-title":"Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis","volume":"82","author":"Jordan","year":"1987","journal-title":"Am J Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/08916930600739712","article-title":"Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases","volume":"39","author":"Fischetti","year":"2006","journal-title":"Autoimmunity"},{"key":"B91","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0923-1811(91)90055-3","article-title":"Decreased expression of decay-accelerating factor on endothelial cells of immune complex-mediated vasculitic skin lesions","volume":"2","author":"Boom","year":"1991","journal-title":"J Dermatol Sci"},{"key":"B92","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1067\/mai.2000.105706","article-title":"Chronic urticaria","volume":"105","author":"Greaves","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jaci.2004.02.049","article-title":"Chronic urticaria: pathogenesis and treatment","volume":"114","author":"Kaplan","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1067\/mjd.2002.122759","article-title":"Chronic urticaria","volume":"46","author":"Grattan","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1056\/NEJMcp011186","article-title":"Clinical practice. Chronic urticaria and angioedema","volume":"346","author":"Kaplan","year":"2002","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"B97","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11882-006-0058-8","article-title":"Autoimmunity and complement in the pathogenesis of chronic urticaria","volume":"6","author":"Marsland","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"B98","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12016-017-8628-1","article-title":"Urticaria and angioedema: an update on classification and pathogenesis","volume":"54","author":"Radonjic-Hoesli","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0091-6749(96)70230-0","article-title":"Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria","volume":"98","author":"Zweiman","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0091-6749(99)70129-6","article-title":"Complement dependence of histamine release in chronic urticaria","volume":"104","author":"Ferrer","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1067\/mai.2002.120954","article-title":"A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria","volume":"109","author":"Kikuchi","year":"2002","journal-title":"J Allergy ClinImmunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S0025-7125(16)31571-1","article-title":"Urticaria and urticarial vasculitis","volume":"64","author":"Monroe","year":"1980","journal-title":"Med Clin North Am"},{"key":"B103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0091-6749(83)90096-9","article-title":"Histologic studies of chronic idiopathic urticaria","volume":"71","author":"Natbony","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1346-8138.2000.tb02142.x","article-title":"Correlation between deposition of immuno-components and infiltration pattern of polymorphonuclear leukocytes in the lesions of chronic urticaria","volume":"27","author":"Sugita","year":"2000","journal-title":"J Dermatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/archderm.115.10.1192","article-title":"Urticaria. An immunofluorescence and histopathology study","volume":"115","author":"Synkowski","year":"1979","journal-title":"Arch Dermatol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.iac.2004.01.007","article-title":"Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome","volume":"24","author":"Davis","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"B107","first-page":"340","article-title":"Hypocomplementemia with cutaneous vasculitis and arthritis. Possible immune complex syndrome","volume":"48","author":"McDuffie","year":"1973","journal-title":"Mayo Clin Proc"},{"key":"B108","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00002281-200001000-00005","article-title":"Urticarial vasculitis","volume":"12","author":"Wisnieski","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/0190-9622(92)70069-R","article-title":"Urticarial vasculitis: a histopathologic and clinical review of 72 cases","volume":"26","author":"Mehregan","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/art.1780370718","article-title":"Hypocomplementemic urticarial vasculitis syndrome in identical twins","volume":"37","author":"Wisnieski","year":"1994","journal-title":"Arthritis Rheum"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/art.38010","article-title":"DNASE1L3 mutations in hypocomplementemic urticarial vasculitis syndrome","volume":"65","author":"Ozcakar","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12026-008-8028-y","article-title":"Complement and cutaneous autoimmune blistering diseases","volume":"41","author":"Lessey","year":"2008","journal-title":"Immunol Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1468-3083.2004.01132.x","article-title":"Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis","volume":"19","author":"Preisz","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0140-6736(73)93006-7","article-title":"Alternate-pathway complement fixation by IgA in the skin in dermatitis herpetiformis","volume":"2","author":"Seah","year":"1973","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/1523-1747.ep12259679","article-title":"Deposition of the membrane attack complex of complement in bullous pemphigoid","volume":"82","author":"Dahl","year":"1984","journal-title":"J Invest Dermatol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1172\/JCI107288","article-title":"The complement system in bullous pemphigoid. I. Complement and component levels in sera and blister fluids","volume":"52","author":"Jordon","year":"1973","journal-title":"J Clin Invest"},{"key":"B117","doi-asserted-by":"publisher","first-page":"72s","DOI":"10.1111\/1523-1747.ep12275497","article-title":"Immunopathologic mechanisms in pemphigus and bullous pemphigoid","volume":"85","author":"Jordon","year":"1985","journal-title":"J Invest Dermatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1600-0560.2008.01129.x","article-title":"C4d immunohistochemical stain is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in bullous pemphigoid","volume":"36","author":"Chandler","year":"2009","journal-title":"J Cutan Pathol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/DAD.0000000000000943","article-title":"Bullous pemphigoid: use of C4d immunofluorescent staining in a case with repeated negative conventional direct immunofluorescence studies","volume":"39","author":"Kassaby","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jaad.2008.06.022","article-title":"The use of C3d and C4d immunohistochemistry on formalin-fixed tissue as a diagnostic adjunct in the assessment of inflammatory skin disease","volume":"59","author":"Magro","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1600-0560.2009.01450.x","article-title":"C3d immunohistochemistry on formalin-fixed tissue is a valuable tool in the diagnosis of bullous pemphigoid of the skin","volume":"37","author":"Pfaltz","year":"2010","journal-title":"J Cutan Pathol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/DAD.0000000000000333","article-title":"Application of C4d immunohistochemistry on routinely processed tissue sections for the diagnosis of autoimmune bullous dermatoses","volume":"38","author":"Villani","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"B124","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1074\/jbc.M111.221036","article-title":"The C5a receptor on mast cells is critical for the autoimmune skin-blistering disease bullous pemphigoid","volume":"286","author":"Heimbach","year":"2011","journal-title":"J Biol Chem"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1172\/JCI17891","article-title":"Role of different pathways of the complement cascade in experimental bullous pemphigoid","volume":"116","author":"Nelson","year":"2006","journal-title":"J Clin Invest"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1172\/JCI11494","article-title":"Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid","volume":"108","author":"Chen","year":"2001","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun"},{"key":"B129","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","article-title":"Humanization of autoantigen","volume":"13","author":"Nishie","year":"2007","journal-title":"Nat Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bjd.14822","article-title":"Complement in bullous pemphigoid: results from a large observational study","volume":"176","author":"Romeijn","year":"2017","journal-title":"Br J Dermatol"},{"key":"B134","first-page":"529","article-title":"Drug evaluation: the C5a receptor antagonist PMX-53","volume":"8","author":"Kohl","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/nbt1342","article-title":"Complement-targeted therapeutics","volume":"25","author":"Ricklin","year":"2007","journal-title":"Nat Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T03:51:17Z","timestamp":1693626677000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2018.00639"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00639","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"article-number":"639"}}